Analyst Price Targets — JSPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 9, 2025 11:19 am | Gregory Renza | RBC Capital | $48.00 | $17.71 | TheFly | Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital |
| December 5, 2024 9:06 pm | Etzer Darout | BMO Capital | $63.00 | $21.53 | StreetInsider | BMO Capital Starts Jasper Therapeutics (JSPR) at Outperform |
| May 6, 2024 6:06 am | Emily Bodnar | H.C. Wainwright | $65.00 | $24.52 | StreetInsider | H.C. Wainwright Starts Jasper Therapeutics (JSPR) at Buy, "an underappreciated gem in the autoimmune and inflammatory disease space" |
| April 3, 2024 6:38 am | Gavin Clark-Gartner | Evercore ISI | $65.00 | $26.20 | StreetInsider | Evercore ISI Starts Jasper Therapeutics (JSPR) at Outperform |
| February 7, 2023 7:38 am | — | Cantor Fitzgerald | $6.00 | $1.92 | Benzinga | Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Lowers Price Target to $6 |
| January 11, 2023 8:08 am | — | Credit Suisse | $3.00 | $1.65 | Benzinga | Credit Suisse Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $3 |
Latest News for JSPR
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the…
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points
Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8 th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for JSPR.
U.S. House Trading
No House trades found for JSPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.